New anesthetic patch is launched
Zars Pharma has announced the launch of Synera (lidocaine 70 mg/tetracaine 70 mg), a topical patch approved for the prevention of pain associated with superficial venous access and superficial dermatological procedures such as excision, electrodessication, and shave biopsy of skin lesions in patients four months of age and older. Zars Pharma has licensed Synera to Endo Pharmaceuticals for sales and marketing in North America. According
New anesthetic patch is launched
Zars Pharma has announced the launch of Synera (lidocaine 70 mg/tetracaine 70 mg), a topical patch approved for the prevention of pain associated with superficial venous access and superficial dermatological procedures such as excision, electrodessication, and shave biopsy of skin lesions in patients four months of age and older. Zars Pharma has licensed Synera to Endo Pharmaceuticals for sales and marketing in North America. According to a company executive, Synera provides local dermal anesthesia in 20 to 30 minutes and the most common local reactions include erythema, blanching, and edema.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
